ClinicalTrials.gg
Active, not recruitingNCT05910840Support-tUpdated Oct 9, 2026

Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care

An interventional study of Support-t in Diabetes Mellitus, Diabetes Mellitus, Type 1 and Glucose Metabolism Disorders (Including Diabetes Mellitus), sponsored by Anne-Sophie Brazeau. Active, not recruiting at 4 sites in Canada. Open to participants aged 14 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Anne-Sophie Brazeau · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 9, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
14 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 319 studies in Diabetes Mellitus, Type 1 with a site in Canada — 49 open to participants now, 61 under way, 15 of them phase 3. Diabetes Mellitus, Type 1 · Canada.

Planned enrollment
68th of 275
200 · median 45
Started
2024
with 14 others
No phase
99 of 319
21 open now
Primary completion
2027-09
later than 38 of 60 live
Registered
275th of 319
by date

Among the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada, this one is the 68th largest by planned enrollment of the 275 interventional ones that give a count, is one of 15 that started in 2024, is one of 99 with no phase, reaches primary completion later than 38 of the 60 other live ones, and was the 275th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

49 of the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 14 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 319 studies in Diabetes Mellitus, Type 1 with a site in Canada, or all of them as a file.
02

Study summary

The investigators will conduct a randomized controlled trial (RCT) to examine how an online training and peer support platform could help the preparation to transition to adult care. Among 14-16 year old youth with Type 1 Diabetes (T1D), the investigators aim to assess the effect of an online training and peer support platform (Support-t) integrated in usual care, compared with usual care on Hemoglobin A1c (HbA1c), adverse outcomes and psychosocial measures during the preparation for transition to adult care. The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in the province of Quebec.

Read the detailed description

The transition from pediatric to adult diabetes care is a challenging period for adolescents and young adults living with chronic conditions, such as Type 1 Diabetes (T1D). For youth with T1D, transition from pediatric to adult care is characterized by deterioration in glycemic control (Hemoglobin A1c [HbA1c]), reduced adherence to diabetes management tasks and increased risk of diabetes complications. The investigators propose to examine an online training and peer support platform as a potential alternative for delivering transition care. In adolescents with T1D, the investigators hypothesize that an online training and peer support platform (Support-t), when integrated into usual pediatric care, as compared with usual care alone, will result in better HbA1c, less adverse outcomes and better psychosocial outcomes during the preparation for transfer to adult care.

Primary Aim: To determine the impact of adding access to Support-t to usual care compared with usual care alone, on HbA1c during the preparation for transfer to adult care.

Secondary Aims: To determine the impact of adding access to Support-t to usual care compared with usual care alone, on self-efficacy, diabetes distress, quality of life (QOL; diabetes specific), readiness to transfer to adult care, glucose management, severe hypoglycemic episodes, diabetic ketoacidosis (DKA), T1D-related ED-visits and hospitalizations during the preparation for transfer to adult care. 2. To determine the cost-effectiveness of Support-t. 3. To understand the context for implementation in regards to level of engagement on Support-t, satisfaction and experience (barriers, facilitators) with Support-t.

Methods: The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec. Patients will be recruited over 20 months. Interventions will occur over 18 months. Follow-up will be to 18 months from enrollment. Allocation will be concealed with a 1:1 intervention to control ratio. Participants in the active arm will have access to a mobile-based online training and peer support platform (Support-t) added to usual care. Participants in the control group will have in parallel with the intervention group, their usual diabetes care. The primary outcome is the change in HbA1c measured at 18 months (HbA1c measured at 18 months - HbA1c measured at baseline). Secondary outcomes are self-efficacy, diabetes distress, QOL, readiness to transfer, glucose management, severe hypoglycemic episodes, DKA, T1D-related ED-visits and hospitalizations. Assessments are at baseline, 6, 12 and 18 months. Analysis will be by intention-to-treat. Outcomes will be calculated and compared between the 2 trial arms using differences with 95% Confidence Intervals, along with a cost-effectiveness analysis. Interviews will be conducted to analyze the context for implementation.

03

Conditions studied

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 1
  • Glucose Metabolism Disorders (Including Diabetes Mellitus)
  • Metabolic Disease
  • Endocrine System Diseases
  • Autoimmune Diseases
  • Immune System Diseases

Keywords

  • Transition Care
  • Pediatric
  • Adolescent
  • Education
  • Hemaglobin A1c
  • Self-management
  • Randomized Controlled Trial
04

In context

Diabetes Mellitus, Type 1 Reclassified

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 200 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

This is the only study on the registry with Anne-Sophie Brazeau as lead sponsor.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
14 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents with a clinical diagnosis of T1D
  • 14-16 years of age
  • Receiving diabetes care at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec: Montreal Children's Hospital-McGill University Health Centre, Centre hospitalier universitaire de Sherbrooke, Le Copain-Hôpital de Gatineau, Centre Hospitalier Universitaire de Québec
  • Having access to internet
  • Having an active email address
  • Fluent in English or French

Exclusion criteria

Exclusion Criteria:

  • Severe neurocognitive disabilities
  • Patients with conditions associated with shortened erythrocyte survival, such as hemolytic anemia or other conditions associated with inaccurate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Support-t plus usual diabetes care

    Access to the Support-t online training and peer support platform in addition to usual diabetes care for 18 months. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Health care providers from the pediatric diabetes clinics will receive Support-t training and will be encouraged to recommend the Support-t platform during routine care with their patients from the active arm.

    Other: Support-t

  • No intervention
    Usual diabetes care only

    Usual diabetes care for 18 months, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians. Health care providers from the pediatric diabetes clinics will be instructed not to discuss or refer to the Support-t platform with patients from the control arm. Control arm participants will have the option to use the Support-t platform after the 18-month study.

Interventions

  • OtherSupport-t

    Support-t plus usual diabetes care for 18 months

07

What researchers measure

Primary outcomes

  1. Change from Baseline Hemaglobin A1c (HbA1c) at 18 months

    HbA1c measured with a venous or capillary blood sample as part of the standard of diabetes care will be derived from the medical record chart or measured using an A1c Test Kit, which is a non-fasting, finger prick, whole blood test

    Time frame: 18 months

Secondary outcomes

  1. Change from Baseline Hemaglobin A1c (HbA1c) at 6 and 12 months

    HbA1c measured with a venous or capillary blood sample as part of the standard of diabetes care will be derived from the medical record chart or measured using an A1c Test Kit, which is a non-fasting, finger prick, whole blood test

    Time frame: 6, 12 months

  2. Continuous Glucose Monitoring (CGM) - % Time in range

    % Time in range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart

    Time frame: 0, 6, 12, 18 months

  3. Continuous Glucose Monitoring (CGM) - % Time above range

    % Time above range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart

    Time frame: 0, 6, 12, 18 months

  4. Continuous Glucose Monitoring (CGM) - % Time below range

    % Time below range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart

    Time frame: 0, 6, 12, 18 months

  5. Continuous Glucose Monitoring (CGM) - Standard deviation

    Standard deviation of the past 4 weeks will be derived from the medical record chart

    Time frame: 0, 6, 12, 18 months

  6. Continuous Glucose Monitoring (CGM) - % Coefficient of variation

    % Coefficient of variation of the past 4 weeks will be derived from the medical record chart

    Time frame: 0, 6, 12, 18 months

  7. Severe hypoglycemic events

    Any severe hypoglycemic events in the past 6 months will be derived from self-report and from the medical record chart

    Time frame: 0, 6, 12, 18 months

  8. Diabetic Ketoacidosis (DKA) events

    Any Diabetic Ketoacidosis (DKA) events in the past 6 months will be derived from self-report and from the medical record chart

    Time frame: 0, 6, 12, 18 months

  9. Diabetes-related hospitalizations

    Any diabetes-related hospitalizations in the past 6 months, expressed as number of hospitalizations per person-years (P-Y) at risk will be derived from self-report and from the medical record chart

    Time frame: 0, 6, 12, 18 months

  10. Diabetes-related emergency department visits

    Any diabetes-related emergency-department visits in the past 6 months, expressed as number of emergency department visits per person-years (P-Y) at risk will be derived from self-report and from the medical record chart

    Time frame: 0, 6, 12, 18 months

  11. Self-efficacy

    Self-efficacy for Diabetes Self-Management Measure (SEDM) assesses self-efficacy. The score ranges from 1 to 10. All item scores are averaged to compute the score. A higher score represents a better outcome.

    Time frame: 0, 6, 12, 18 months

  12. Diabetes distress

    Problem Areas in Diabetes Scale-Teen (PAID-T) assesses adolescent diabetes distress. The scores range from 14 to 84. A total distress score is computed by summing responses. Higher scores indicate youth perception of feeling more burdened related to T1D.

    Time frame: 0, 6, 12, 18 months

  13. Diabetes specific Quality of Life (QOL)

    Type 1 Diabetes and Life (T1DAL) questionnaire assesses diabetes specific QOL for 12-17 year old adolescents living with T1D. Scores are transformed on a scale from 0 to 100. The total score ranges from 0 to 100. To calculate the total score, the mean is computed as the sum of all item scores divided by the number of items answered on all the scales. A higher total score represents a better outcome. The subscale scores (Daily Emotional Experiences \& Daily Activities, Handling Diabetes Well, Peer Relationships, and Family Relationships) range from 0 to 100. To calculate the subscale scores, the mean is computed as the sum of the items in the subscale divided by the number of items answered on the subscale. Higher subscale scores represent a better outcome.

    Time frame: 0, 6, 12, 18 months

  14. Transition readiness

    Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) assesses diabetes-related knowledge or skill items by querying respondents on 42 total items split into 5 domains: knowledge, navigation, health behaviors, and insulin pump skills. Respondents answer on a Likert scale from "yes, I can do this" scored 5 to "Haven't thought about it" scored 1. Confidence level is evaluated in each domain with a higher score indicating more confidence.

    Time frame: 0, 6, 12, 18 months

  15. Cost effectiveness (HbA1c)

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for HbA1c

    Time frame: 12 and 18 months

  16. Cost effectiveness (self-efficacy)

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for self-efficacy

    Time frame: 12 and 18 months

  17. Cost effectiveness (diabetes distress)

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for diabetes distress

    Time frame: 12 and 18 months

  18. Cost effectiveness (QOL)

    Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for QOL

    Time frame: 12 and 18 months

Other outcomes

  1. Engagement with Support-t platform (T1D patient) - time in minutes on platform

    Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform

    Time frame: 6, 12, 18 months

  2. Engagement with Support-t platform (T1D patient) - discussion forum participation

    Engagement metrics will be extracted using Google analytics - participation on the platform discussion forum

    Time frame: 6, 12, 18 months

  3. Engagement with Support-t platform (T1D patient) - content accessed

    Engagement metrics will be extracted using Google analytics - specific content accessed from the platform

    Time frame: 6, 12, 18 months

  4. Engagement with Support-t platform (T1D patient) - total pages viewed

    Engagement metrics will be extracted using Google analytics - total pages viewed from the platform

    Time frame: 6, 12, 18 months

  5. Engagement with Support-t platform (T1D patient) - downloaded documents

    Engagement metrics will be extracted using Google analytics - downloaded documents from the platform

    Time frame: 6, 12, 18 months

  6. Engagement with Support-t platform (T1D patient) - use of calculators

    Engagement metrics will be extracted using Google analytics - use of calculators on the platform

    Time frame: 6, 12, 18 months

  7. Engagement with Support-t platform (Health Care Provider) - time in minutes on platform

    Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform

    Time frame: 6, 12 months

  8. Engagement with Support-t platform (Health Care Provider) - content accessed

    Engagement metrics will be extracted using Google analytics - specific content accessed from the platform

    Time frame: 6, 12 months

  9. Engagement with Support-t platform (Health Care Provider) - total pages viewed

    Engagement metrics will be extracted using Google analytics - total pages viewed from the platform

    Time frame: 6, 12 months

  10. Engagement with Support-t platform (Health Care Provider) - downloaded documents

    Engagement metrics will be extracted using Google analytics - downloaded documents from the platform

    Time frame: 6, 12 months

  11. Engagement with Support-t platform (Health Care Provider) - use of calculators

    Engagement metrics will be extracted using Google analytics - use of calculators on the platform

    Time frame: 6, 12 months

  12. Satisfaction with Support-t platform - T1D patient

    Satisfaction will be rated on a scale from 1 to 10. Higher scores indicate greater satisfaction with the platform.

    Time frame: 6, 12, 18 months

  13. Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - T1D patient

    Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology

    Time frame: 18 months

  14. Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider

    Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology

    Time frame: 12 months

08

Study locations

4 sites
09

References and documents

Publications

  • Sanmugalingham G, Mok E, Cafazzo JA, Desveaux L, Brazeau AS, Booth GL, Greenberg M, Kichler J, Rac VE, Austin P, Goldbloom E, Henderson M, Landry A, Zenlea I, Taylor M, Nakhla M, Shulman R. Text message-based intervention, Keeping in Touch (KiT), to support youth as they transition to adult type 1 diabetes care: a protocol for a multisite randomised controlled superiority trial. BMJ Open. 2023 May 8;13(5):e071396. doi: 10.1136/bmjopen-2022-071396. PubMed 37156577 ↗
  • Xie LF, Housni A, Nakhla M, Cianci R, Leroux C, Da Costa D, Brazeau AS. Adaptation of an Adult Web Application for Type 1 Diabetes Self-management to Youth Using the Behavior Change Wheel to Tailor the Needs of Health Care Transition: Qualitative Interview Study. JMIR Diabetes. 2023 Apr 26;8:e42564. doi: 10.2196/42564. PubMed 37121571 ↗
  • Ladd JM, Reeves-Latour J, Dasgupta K, Bell LE, Anjachak N, Nakhla M. Toward a better understanding of transition from paediatric to adult care in type 1 diabetes: A qualitative study of adolescents. Diabet Med. 2022 May;39(5):e14781. doi: 10.1111/dme.14781. Epub 2022 Jan 7. PubMed 34967058 ↗
  • Mok E, Henderson M, Dasgupta K, Rahme E, Hajizadeh M, Bell L, Prevost M, Frei J, Nakhla M. Group education for adolescents with type 1 diabetes during transition from paediatric to adult care: study protocol for a multisite, randomised controlled, superiority trial (GET-IT-T1D). BMJ Open. 2019 Nov 11;9(11):e033806. doi: 10.1136/bmjopen-2019-033806. PubMed 31719096 ↗
  • Alwadiy F, Mok E, Dasgupta K, Rahme E, Frei J, Nakhla M. Association of Self-Efficacy, Transition Readiness and Diabetes Distress With Glycemic Control in Adolescents With Type 1 Diabetes Preparing to Transition to Adult Care. Can J Diabetes. 2021 Jul;45(5):490-495. doi: 10.1016/j.jcjd.2021.05.006. Epub 2021 May 19. PubMed 34176613 ↗
  • Michaud S, Dasgupta K, Bell L, Yale JF, Anjachak N, Wafa S, Nakhla M. Adult care providers' perspectives on the transition to adult care for emerging adults with Type 1 diabetes: a cross-sectional survey. Diabet Med. 2018 Jul;35(7):846-854. doi: 10.1111/dme.13627. Epub 2018 May 2. PubMed 29577410 ↗
  • Lafontaine S, Mok E, Frei J, Henderson M, Rahme E, Dasgupta K, Nakhla M. Associations of Diabetes-related and Health-related Quality of Life With Glycemic Levels in Adolescents With Type 1 Diabetes Preparing to Transition to Adult Care. Can J Diabetes. 2023 Aug;47(6):525-531. doi: 10.1016/j.jcjd.2023.05.002. Epub 2023 May 12. PubMed 37182591 ↗
  • Soufi A, Mok E, Henderson M, Dasgupta K, Rahme E, Nakhla M. Association of stigma, diabetes distress and self-efficacy with quality of life in adolescents with type 1 diabetes preparing to transition to adult care. Diabet Med. 2024 Jan;41(1):e15159. doi: 10.1111/dme.15159. Epub 2023 Jun 21. PubMed 37269172 ↗
  • Wafa S, Nakhla M. Improving the Transition from Pediatric to Adult Diabetes Healthcare: A Literature Review. Can J Diabetes. 2015 Dec;39(6):520-8. doi: 10.1016/j.jcjd.2015.08.003. Epub 2015 Oct 20. PubMed 26498219 ↗
  • Nakhla M, Daneman D, To T, Paradis G, Guttmann A. Transition to adult care for youths with diabetes mellitus: findings from a Universal Health Care System. Pediatrics. 2009 Dec;124(6):e1134-41. doi: 10.1542/peds.2009-0041. Epub 2009 Nov 23. PubMed 19933731 ↗
  • Nakhla M, Daneman D, Frank M, Guttmann A. Translating transition: a critical review of the diabetes literature. J Pediatr Endocrinol Metab. 2008 Jun;21(6):507-16. PubMed 18717235 ↗
  • Nakhla M, Bell LE, Wafa S, Dasgupta K. Improving the transition from pediatric to adult diabetes care: the pediatric care provider's perspective in Quebec, Canada. BMJ Open Diabetes Res Care. 2017 Jun 30;5(1):e000390. doi: 10.1136/bmjdrc-2017-000390. eCollection 2017. PubMed 28761657 ↗
  • Robinson ME, Simard M, Larocque I, Shah J, Rahme E, Nakhla M. Psychiatric disorders in emerging adults with diabetes transitioning to adult care: A retrospective cohort study. Diabet Med. 2021 Jun;38(6):e14541. doi: 10.1111/dme.14541. Epub 2021 Feb 19. PubMed 33576092 ↗
  • Roy-Fleming A, Nakhla M, Mok E, Vanasse A, Cianci L, Kichler J, Simoneau-Roy J, Couture Y, Gagne J, Dupont M, Brazeau AS. Support-t, an online training and peer support platform to accompany youth living with type 1 diabetes transitioning to adult healthcare: protocol of an effectiveness-implementation trial. BMJ Open. 2025 Oct 6;15(10):e105514. doi: 10.1136/bmjopen-2025-105514. PubMed 41057177 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 35 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2027 → Sep 2027 and completion Oct 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 20, 2023
StartActual
Oct 7, 2024
Primary completionEst.
Sep 30, 2027was Apr 2027
CompletionEst.
Jan 1, 2028was Oct 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 9, 2026
Primary completion
Apr 2027→Sep 30, 2027
Oct 9, 2026
Study completion
Oct 2027→Jan 1, 2028
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Active, not recruiting
    Primary completion Apr 2027→Sep 30, 2027
    Study completion Oct 2027→Jan 1, 2028
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05910840
Lead sponsor
Anne-Sophie Brazeau
Responsible party
Anne-Sophie Brazeau (Associate Professor, McGill University) — Sponsor-investigator
First posted
Jun 20, 2023
Start date
Oct 7, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Anne-Sophie Brazeau, PhD
principal investigator · School of Human Nutrition - McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion